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Cardiovascular disease is the leading cause of death among women in the U.S., exceeding
breast cancer mortality in women of all ages. Women present with cardiovascular disease a
decade after men, and this has been attributed to the protective effect of female ovarian sex
hormones that is lost after menopause. Animal and observational studies have shown
beneficial effects of hormone therapy when it is initiated early in the perimenopausal period
or before the development of significant atherosclerosis. However, randomized, placebo-
controlled trials in older women have not shown any benefit in either primary prevention or
secondary prevention of cardiovascular events, with a concerning trend toward harm. This
review outlines the lessons learned from the basic science, animal, observational, and
randomized trials, and then summarizes yet-unanswered questions of hormone therapy and
cardiovascular risk. (J Am Coll Cardiol 2006;47:1741–53) © 2006 by the American College
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.10.076of Cardiology Foundation
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vardiovascular disease is the leading cause of death among
omen in the U.S., accounting for more than 500,000
eaths annually (1). Mortality attributable to coronary heart
isease (CHD) exceeds breast cancer mortality in women at all
ges (2). The vast majority of these cardiovascular events occur
n postmenopausal women. Heart disease develops in women
n average 10 years later in life compared with men, and this
ag has been attributed to the protective effects of female sex
ormones, particularly estrogens, before menopause (3).
Initially, data from animal studies and observational
tudies such as the Nurses’ Health Study (4) strongly
upported a protective cardiovascular benefit of hormone
herapy (HT) after menopause, an effect not supported by
andomized placebo-controlled trials in both secondary
revention (5) and primary prevention (6), which instead
howed a concerning trend toward harm. However, many
nanswered questions remain.
This review outlines lessons learned from basic science of
strogen action and animal studies and from observational
nd randomized trials, followed by a discussion of as-yet-
nanswered questions about HT and cardiovascular risk.
OLECULAR AND CELLULAR
ASIS OF ESTROGEN IN VASCULAR BIOLOGY
strogen can have both positive and negative effects on the
ardiovascular system (7) (Fig. 1). On the positive side,
From the *Division of Cardiology, Johns Hopkins University School of Medicine,
altimore, Maryland; and the †Molecular Cardiology Research Center and the
ivision of Cardiology, Tufts-New England Medical Center, Boston, Massachusetts.
r. Ouyang was supported by grants M01RR02719 and R01HL074406 from the
ational Institutes of Health. Dr. Karas is an Established Investigator for ther
merican Heart Association.
Manuscript received October 5, 2005; accepted October 21, 2005.strogen has potentially beneficial effects on lipid parame-
ers, such as reducing low-density lipoprotein cholesterol
LDLC) and increasing high-density lipoprotein choles-
erol (HDLC), facilitating nitric oxide-mediated vasodila-
ion, and inhibiting the response of blood vessels to injury
nd the development of atherosclerosis (8). On the negative
ide, estrogens increase triglycerides (9,10) and inflamma-
ory markers such as C-reactive protein (CRP) (11,12).
strogen also has many prothrombotic effects, such as
ncreasing circulating levels of prothrombin and decreasing
ntithrombin III (13,14), contributing to an increased risk
f venous thromboembolic events. Importantly, many of
hese effects of estrogen are mediated by first-pass effects on
he liver, and thus result from oral but not transdermal
dministration of HT. For example, increased levels of CRP
eem to occur only with oral estrogen administration. The
xtent to which this is associated with an increase in
ardiovascular disease risk is uncertain (15,16). These ob-
ervations underscore the potential importance of the mode
f administration on the overall effects of HT on CHD risk
s discussed below.
ECHANISMS OF ESTROGEN ACTION
s our understanding of the mechanisms by which estro-
ens affect the cardiovascular system has increased, it has
ecome clear that the complexity of the biological effects
f estrogens are reflective of quite complex mechanisms of
ction (7,8). As noted above, estrogens regulate a variety of
ystemic or circulating factors, including lipids, inflamma-
ory factors, and members of the coagulation/fibrinolytic
ascades. Estrogens can also act directly on the heart and the
asculature. The effects of estrogen are mediated by estrogen
eceptors, of which two are known, ER and ER, and
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strogen receptors are classically thought of as ligand-
ctivated transcription factors that reside in the cell nucleus
nd regulate gene expression in response to hormone
inding. This mechanism, often referred to as the genomic
athway, likely underlies the longer-term effects of estrogen,
uch as those on circulating levels of lipids and coagulation
actors. More recently it has become clear that estrogen
eceptors also transduce the rapid effects of estrogen that
ccur within minutes (17) and are referred to as non-
Abbreviations and Acronyms
CHD  coronary heart disease
CI  confidence interval
CRP  C-reactive protein
HDLC  high-density lipoprotein cholesterol
HT  hormone therapy
IMT  intima-medial thickness
LDLC  low-density lipoprotein cholesterol
MI  myocardial infarction
MPA  medroxyprogesterone acetate
igure 1. Estrogen: beneficial and thrombogenic effects. CAM  cell adh
ormone replacement therapy; LDL  low-density lipoprotein; MCP  monoc
umor necrosis factor; VSMC  vascular smooth muscle cell. Reprinted, withenomic because they do not depend on changes in gene
xpression. These rapid effects of estrogen are mediated by
subpopulation of estrogen receptors localized to cell
embrane signaling domains called caveolae. The best-
tudied example of this non-genomic pathway for estrogen
ction in the cardiovascular system is the activation of
ndothelial cell nitric oxide synthase that results in arterial
asodilation in response to acute administration of estrogen.
MPACT OF DISEASE STATE ON THE
ARDIOVASCULAR EFFECTS OF ESTROGEN
here is growing evidence showing that the effects of
strogen on the vasculature depend in part on the extent to
hich atherosclerosis has become established. For example,
strogen receptor expression is markedly diminished in
therosclerotic arteries (18,19), and thus, to the extent that
irect, receptor-dependent effects on the vasculature con-
ribute to the potential for anti-atherosclerotic effects, this
ill be diminished or absent in diseased arteries. In addi-
ion, the effects of estrogen on a given pathway may have
ifferent consequences depending on the state of health of
molecule; Cox-2  cyclooxygenase 2; ER  estrogen receptor; HRT esion
yte chemoattractant protein; MMP  matrix metalloproteinase; TNF 
permission, from Mendelsohn and Karas (7).
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May 2, 2006:1741–53 Hormone Therapy and the Cardiovascular Systemhe underlying vessel. For example, estrogen up-regulates
pecific members of the matrix metalloproteinase (MMP)
amily such as MMP-9 (20). The MMPs degrade the
xtracellular matrix with the arterial wall. Thus, in a
on-diseased artery, an estrogen-induced increase in
MP-9 may have little or no consequences, whereas in an
therosclerotic artery, where MMP-9 is expressed in the
houlder region of an atherosclerotic plaque, an increase in
MP-9 activity could conceivably be associated with an
ncreased risk of plaque rupture and thus acute coronary
yndromes. The Fitzgerald laboratory has recently shown
hat estrogen-mediated up-regulation of cyclooxygenase-2
lays an important role in retarding atherosclerosis in a
ypercholesterolemic mouse model (21). This suggests that
therosclerotic arteries with impaired cyclooxygenase-2 re-
ponses may also lose this potentially beneficial effect of
ormone treatment.
More direct support for the hypothesis that the effects of
strogen on cardiovascular risk depend on the timing of
nitiation of therapy in relation to the extent of underlying
therosclerosis comes from the Clarkson laboratory. Using a
ell-established monkey model of atherosclerosis, Clarkson
nd colleagues have shown that the antiatherosclerotic
ffects of oral conjugated equine estrogens (CEE) are
pparent only in monkeys with minimal underlying athero-
clerosis at the time that therapy is initiated, as reviewed in
aras and Clarkson (20), a finding also supported by rodent
nd rabbit studies (22,23).
ARDIOVASCULAR DISEASE AND MENOPAUSE
nterest in the role estrogen plays in cardiovascular disease
as stimulated by the observed increase in cardiovascular
vents after menopause. In 1976 the Framingham investi-
ators reported a 2.6-fold higher incidence of cardiovascular
vents in age-matched postmenopausal women compared
ith premenopausal women (24). The excess CHD risk
ssociated with surgical menopause was 2.7-fold higher
ompared with premenopausal women of the same age
p  0.01) (25) and 2.2-fold higher compared with women
ith a natural menopause. This excess risk seemed to be
revented by estrogen replacement therapy (26). Plasma
ipoproteins were thought to play a role in the increased
HD risk that menopause confers because total cholesterol,
DL cholesterol, and triglyceride levels all increase in
omen after menopause (27), and HT seemed to counter
hese unfavorable effects of lipids, although the cardiopro-
ective HDL cholesterol levels also decreased (28). In
ddition, there is an age-associated increase in the incidence
f cardiovascular disease for both premenopausal and post-
enopausal women independent of the effects of HT.
verall, however, data indicate that withdrawal of estrogen
uring menopause is associated with an increased risk of
eart disease above that seen for premenopausal women.
his led to interest in the potential cardiovascular benefitrom postmenopausal estrogen replacement therapy. aNIMAL STUDIES OF HORMONE REPLACEMENT
n animal studies, estrogens exert vasodilator (29), anti-
nflammatory (30), and antiatherosclerotic (31) properties,
s well as favorably affecting lipid profiles. In a study of
andomized ovariectomized hypercholesterolemic rabbits,
stradiol significantly reduced atherosclerosis progression
ompared with levonorgestrel or no hormones (32). A series
f studies have also shown that estradiol significantly lessens
he response to vascular injury in mice and further implicate
R as the specific estrogen receptor that mediates this
asculoprotective effect (33–36). Similarly in ovariectomized
onkeys, 17-estradiol or CEE reduced coronary artery
therosclerosis compared with control animals by 50% (p 
.05) (37) to 72% (p  0.04) (38). Although the role of
strogen replacement seemed promising in the animal studies,
he data regarding progesterone were more conflicting (39).
BSERVATIONAL TRIALS
F HORMONE REPLACEMENT
verall, the animal studies suggested a promising role of
strogen replacement after menopause. Simultaneously, a
eries of observational and case-control trials also suggested
enefit (reviewed in Table 1). The majority of the smaller
ase-control studies (40–45) showed nonsignificant trends
oward reduction in CHD events with overall odds ratios
anging from 0.69 to 0.9. However, a large case-control
tudy did show a significant association with HT and
educed incidence of first myocardial infarction (MI) (46).
onger duration of use seemed to confer even more cardio-
ascular benefit (47).
In addition to reducing CHD events, cross-sectional data
uggested less subclinical atherosclerosis in HT users (48).
n an observational analysis of the Cardiovascular Health
tudy of women 65 years of age, estrogen users had lower
evels of subclinical disease as measured by a variety of
urrogate end points (49). Even more promising, the much
arger observational Nurses’ Health Study of 70,000 asymp-
omatic women showed a lower incidence of CHD events
nd all-cause mortality in HT users compared with nonus-
rs (4,50,51). It is important to note that most women in the
urses’ Health Study likely started taking HT in the
erimenopausal period and were free of known CHD at the
tart of the study.
ANDOMIZED TRIALS
F HORMONE REPLACEMENT THERAPY
he animal and observational studies were followed by a
eries of randomized, placebo-controlled trials of HT in
oth primary and secondary prevention, and with both
urrogate and cardiovascular event outcomes, which failed
o confirm cardiovascular benefit (reviewed in Table 2).
lthough two smaller randomized trials using the surrogate
nd points of carotid intima-medial thickness (IMT) (52)
nd brachial reactivity (53) favored estrogen, three other
Table 1. Observational and Case-Controlled Studies of Hormone Therapy
Investigator/
Year Type of Study Population Hormone Preparation
Primary
End Point Results Conclusions
Rosenberg et al.
(40)/1993
Case-controlled 858 women age 45–60 yrs
with first MI compared with
858 age-matched control
subjects.
Estrogen (E) alone: 21% of both
cases and control subjects used
E; most using CEE.
First MI OR of 0.9 (0.7–1.2) with
history of E use. For
5 yrs of use OR of 0.6
(p  0.08).
Nonsignificant trend toward
reduced first MI in E
users, longer-term use
was stronger than recent
use (p  0.05) and
compared with past use
(p  0.08).
Mann et al.
(41)/1994
Case-controlled Database within British
National Health Service.
Women age 45–64 yrs
(n  567,096), with 1,521
cases of MI matched with
6,084 control subjects.
Any E or E progestin (P):
117 cases and 562 control
subjects used HT.
Approximately 2/3 on EP
and 1/3 on E.
First MI (fatal or
nonfatal)
OR 0.83 (0.66–1.03),
p  0.089 with HT use.
Nonsmokers on HT, OR
0.70 (0.49–1), smokers on
HT, OR 1.05 (0.71–1.53).
Nonsignificant trend toward
reduced first MI with any
form of HT. However,
protective effect seems to
be confined to
nonsmokers.
Psaty et al.
(42)/1994
Case-controlled Group Health Cooperative of
Puget Sound, WA.
Postmenopausal women,
502 cases of MI and
1,193 control subjects.
Any E or EP. Among cases,
HT use was E (n  45) and
EP (n  16); among
control subjects use was
E (n  157) and EP (n 
74). Majority used cyclical
0.625 CEE and 10 mg MPA.
First MI (fatal or
nonfatal)
OR 0.69 (0.47–1.02) with E
alone. OR 0.68 (0.38–1.22)
with EP.
Nonsignificant trend toward
reduced risk of MI.
Jonas et al.
(48)/1996
Cross-sectional,
nonrandomized
2,962 women in the
Cardiovascular Health
Study.
E formulation not specified. Past
users (n  787), current E
alone (n  280), current EP
(n  73).
Carotid IMT
Carotid stenosis
IMT was 0.22 mm less in E
(p  0.003) and 0.09 mm
less in EP (p  0.05) vs.
in nonusers. Adjusted OR
for carotid stenosis of 0.61
(0.36–1.01) for E and OR
0.91 (0.67–1.25) for EP.
Both EP and E alone
were associated with
decreased measures of
carotid atherosclerosis.
Grodstein et al.
(4)/1996
Prospective
observational
59,337 women from Nurses’
Health Study ages 30–55 yrs
at baseline. 770 cases of MI/
CHD death and
572 cases of stroke over
16-yr follow-up.
Past users (n  12,503), current
E alone (n  7,776), and
EP (n  6,224).
MI or CHD death For MI/CHD events, RR 0.39
(0.19–0.78) in EP, 0.60
(0.43–0.83) in E alone. For
stroke, RR 1.09 (0.66–1.8)
in EP and 1.27
(0.95–1.69) for E alone.
These data support a
reduced risk of hard
CHD events in women
on HT that is not
attenuated by the
addition of progestin.
However, there was a
nonsignificant trend
toward increased strokes.
Continued on next page
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Table 1. Continued
Investigator/
Year Type of Study Population Hormone Preparation
Primary
End Point Results Conclusions
Grodstein et al.
(50)/1997
Prospective
observational
Postmenopausal women of
Nurses’ Health Study. 3,637
cases and 34,625 control
subjects over 18-yr
follow-up.
Any hormone replacement. Mortality RR 0.63 (0.56–0.70) in current
HT users, decreasing after
10 years of use (RR 0.80,
0.67–0.96). Benefit seen in
HT users with CHD risk
factors (RR 0.51,
0.45–0.57), not in those
at low risk (RR 0.89,
0.62–1.28).
Mortality is lower among
current HT users;
however, survival benefit
diminishes over time and
is lower for women at
low risk for CHD.
Heckbert et al.
(47)/1997
Case-controlled Group Health Cooperative of
Puget Sound, WA enrollees.
Postmenopausal women; 850
cases with MI and 1,974
control subjects.
E alone or EP. 229 cases and
700 control subjects used HT,
most commonly CEE with or
without MPA.
Fatal or nonfatal
MI
For categories of duration of E
use, OR 1.0 for never (ref),
0.91 for 1.8 yrs, 0.70 for
1.8–4.2 yrs, 0.64 for 4.2–8.2
yrs, and 0.55 for 8.2 yrs.
p  0.05 for the trend.
A longer duration of HT
among current users was
associated with a reduced
risk of first MI.
Sidney et al.
(43)/1997
Case-controlled Kaiser database. Post-
menopausal women age
45–74 yrs; 438 cases with
MI and 438 age-matched
control subjects.
E or EP. In women s/p
hysterectomy 51% used E,
1.2% used EP. In women
with a uterus 18.4% used
EP, 3% used E.
MI OR 0.96 (0.66–1.49) in current
HT users compared with
nonusers, OR 1.07
(0.72–1.58) in past users.
No statistically significant
decrease in OR for MI in
current or past users of
HT.
Petitti et al.
(44)/2000
Case-controlled Same population of Kaiser
database as above.
As above. MI OR 0.9 (0.5–1.6) in current
HT users without CHD risk
factors, 0.8 (0.5–1.8) with 1
risk factor and 1.1 (0.5–2.2)
with 2 risk factors.
No decrease in risk of MI
in current users of HT
who had 0, 1, 2, or 3
major CHD risk factors.
Grodstein et al.
(45)/1999
Case-controlled Sweden. Postmenopausal
women with 213 cases of
MI and 289 strokes matched
to control subjects.
Medium-potency compared with
low-potency or short-term E
or EP use.
MI and stroke For MI, OR 0.75 (0.56–0.99)
for medium-potency
compared with low-potency
E and OR 0.69 (0.45–0.90)
for combined EP. For
stroke, OR 0.91 (0.71–1.17)
for medium-potency E and
0.81 (0.61–1.10) for EP.
Decreased risk of MI for
medium potency E or
EP. No effect was seen
on stroke risk.
Continued on next page
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Investigator/
Year Type of Study Population Hormone Preparation
Primary
End Point Results Conclusions
Grodstein et al.
(51)/2000
Prospective,
observational
Nurses’ Health Study. 70,533
postmenopausal women with
1,258 fatal/nonfatal MI and
767 strokes over 20-yr
follow-up.
Any HT including CEE 0.3
mg, 0.625 mg, and 1.25 mg
either alone or in combination
with progestin.
Fatal or nonfatal
MI and stroke
CHD events: RR in current E
users of 0.61 (0.52–0.71);
0.54 (0.44–0.67) with CEE
0.625 mg and 0.58
(0.37–0.92) with CEE
0.3 mg. Stroke: RR 1.35
(1.08–1.68) with CEE 0.625
mg, 1.63 (1.18–2.26) for
1.25 mg, and 1.45
(1.10–1.92) for EP.
CEE seemed to decrease
the risk of CHD events
with similar reduction for
0.3 mg and 0.625 mg
CEE. However, CEE
0.625 mg or in
combination with
progestin may increase
risk of stroke.
Varas-Lorenzo
et al. (46)/
2000
Case-controlled General Practice Research
Database (n  164,769),
with 1,242 cases of first MI
and 5,000 age-matched
control subjects.
Any HT including oral (79%)
and transdermal (21%)
formulations.
MI Current HT users had OR
0.72 (0.59–0.89), OR 0.52
(0.35–0.78) for E, and OR
0.79 (0.59–1.08) for EP.
Data showed an association
between HT and reduced
incidence of acute MI.
This was similar in users
of oral and transdermal
formulations.
Ferrara et al.
(72)/2003
Observational Kaiser database. Diabetic
women age 50 yrs (mean
age 65 yrs, n  25,000).
Low-, medium-, or high-dose
E alone or combined EP.
There were 2,526 (10%)
women on E alone and
2,088 (9%) on EP.
3-yr MI risk In those without a recent MI,
RH for MI for combined
HT was 0.77 (0.61–0.97);
unopposed estrogen was
0.88 (0.73–1.05). In those
with a recent MI, RH was
1.78 (1.06–2.98).
In diabetic women without
a recent MI, use of HT
was associated with
decreased risk of MI in
women on 0.625 mg
CEE but not a higher
dose. However, HT was
associated with an
increased risk of MI in
women with a history of
recent MI, especially for
HT use 1 yr.
CEE  conjugated equine estrogens; CHD  coronary heart disease; E  estrogen; EP  estrogen plus progestins; HR  hazard ratio; HT  hormone therapy; IMT  intimal-medial thickness; IV  intravenous; MI  myocardial
infarction; MPA  medroxyprogesterone; OR  odds ratio (95% confidence interval); PE  pulmonary embolism; PO  per os (oral); RF  risk factors; RR  relative risk; TIA  transient ischemic attack.
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Table 2. Summary of the Randomized Trials of Hormone Therapy
Investigator/
Year Study Design Subjects Intervention
Median
Follow-Up End Point Results Conclusions
Herrington et al.
(54)/2000
(ERA)
Randomized,
double-blind,
placebo-controlled
secondary prevention trial
309 postmenopausal
women with
coronary stenosis
30%, mean age
65.8 yrs
CEE 0.625 mg only
(n  100), CEE
0.625MPA
2.5 mg daily
(n  104),
or placebo
(n  100)
3.2 yrs Quantitative coronary
angiography:
adjusted change in
mean luminal
diameter
0.09  0.02 mm for E,
0.12  0.02 for combined
EP, and 0.09  0.02 for
placebo, p  0.38
Neither E alone nor
EP affected the
progression of
coronary
atherosclerosis.
Waters et al.
(55)/2002
(WAVE)
Randomized,
double-blind,
placebo-controlled
secondary prevention trial
423 postmenopausal
women with at
least 1 coronary
stenosis 15% to
75%, mean age
65 yrs
CEE 0.625 mg 
MPA 2.5 mg
daily (n  210)
vs. placebo
(n  213), and
vitamins vs.
placebo
2.8 yrs Quantitative coronary
angiography:
annualized mean
change in
minimum lumen
diameter
Coronary progression worsened
with HT by 0.047 (0.15)
mm/yr and by 0.024 (0.015) in
control subjects, p  0.17.
Death, nonfatal MI, or stroke
HR was 1.9 (95% CI 0.97–3.6)
in HT compared with control
subjects.
No significant change
in progression of
atherosclerosis.
Neither HT (nor
antioxidant
supplements)
provided CV
benefit. Instead a
potential for harm
was suggested.
Hodis et al.
(56)/2003
(WELL-
HART)
Randomized,
double-blind,
placebo-controlled
226 postmenopausal
women with
CHD, mean age
63.5 yrs
Oral 17 -estradiol
(1 mg/day) alone
(n  76), 5 mg
MPA (n  74),
or placebo
(n  76)
3.3 yrs Quantitative coronary
angiography:
average per-
participant change
in percent stenosis
Mean change in stenosis was
1.89  0.78 in placebo,
2.18  0.76 in E, 1.24  0.80
in EP; p  0.66 for
comparison
Estrogen alone or with
progesterone had no
significant effect on
the progression of
atherosclerosis.
de Kleijn et al.
(53)/2001
Randomized,
double-blind,
placebo-controlled
primary prevention trial
105 healthy
postmenopausal
women
Tibolone (n  35),
CEEMPA
(n  35), or
placebo (n  35)
3 months Brachial reactivity:
% flow-mediated
lumen diameter
change after
3 months
CEEMPA vs. placebo had
2.5% change (0.3–4.6).
Tibolone vs. placebo was 0.6%
(1.6–2.8).
HT with CEEMPA
(but not tibolone)
increases
endothelium-
dependent flow-
mediated dilation.
Continued on next page
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Table 2. Continued
Investigator/
Year Study Design Subjects Intervention
Median
Follow-Up End Point Results Conclusions
Angerer et al.
(59)/2001
(PHOREA)
Randomized,
double-blind,
placebo-controlled,
secondary prevention
321 healthy
postmenopausal
women with
increased carotid
IMT
17 -estradiol 1 mg 
0.025 mg gestodone
for 12 days/months
vs. every 3 months
(low-progestin)
vs. no HT
48 weeks IMT: maximum
carotid IMT
thickness
HT did not slow carotid IMT
progression
1 yr of HT did not
slow progression of
subclinical
atherosclerosis in
postmenopausal
women at increased
risk.
Hodis et al.
(52)/2001
(EPAT)
Randomized, double-blind,
placebo-controlled,
primary prevention trial
222 healthy
postmenopausal
women without
CHD
Unopposed 17
-estradiol (1 mg)
(n  111) or
placebo
(n  111)
2 yrs IMT: rate of change
in carotid artery
IMT every 6 mo
0.0017 mm/yr in E arm vs.
0.0036 mm/yr, placebo-
estradiol difference in
progression was 0.0053 mm/yr
(0.0001–0.0105 mm/yr,
p  0.046)
Progression of
subclinical
atherosclerosis was
slower in healthy
postmenopausal
women taking
unopposed E,
compared with
placebo.
Byingtoni et al.
(58)/2002
(HERS
B-Mode
substudy)
Randomized, double-blind,
placebo-controlled
secondary prevention trial
362 postmenopausal
women with
CHD (subset of
HERS trial)
CEE 0.625  MPA
2.5 mg (n  177)
or placebo (n  185)
Mean 3.8 yrs IMT: temporal
change in mean of
8 maximum IMT
measurements
IMT progressed 26 m/yr
(18–34) in CEEMPA group
and 31 m/yr (21–40) in
placebo group, p  0.44
IMT progressed in
both groups without
significant
difference.
Schulman et al.
(60)/2001
Randomized, double-blind,
placebo-controlled trial
293 postmenopausal
women
presenting with
unstable angina
enrolled within
24 h of symptom
onset
IV 1.25 mg bolus then
oral CEE 1.25 mg
 MPA 2.5 mg 
21 days vs. IV bolus
then oral CEE 1.25
mg  placebo vs.
IV then oral placebo
48 h ECG evidence of
ischemia by
continuous
ambulatory
monitoring (first
48 h) and repeated
after 21 days of
study drug
ECG ischemia did not differ
among the three groups
Acute HT does not
reduce ischemia in
postmenopausal
women with
unstable angina
when added to
standard anti-
ischemia therapy.
Viscoli et al.
(61)/2001
(Women’s
Estrogen for
Stroke Trial)
Randomized, double-blind,
placebo-controlled
secondary prevention trial
664 postmenopausal
women (mean
age 71 yrs) with
recent stroke or
TIA
17 -estradiol 1 mg Mean 2.8 yrs CV events: recurrent
stroke or death
Combined events: RR 1.1
(0.8–1.4) in E vs. placebo.
Death alone RR 1.2 (0.8–1.8).
Nonfatal stroke RR 1.0
(0.7–1.4). Fatal stroke RR 2.0,
(0.9–9.0) in E users. Nonfatal
strokes had slightly worse
neurologic outcome in E users.
Estradiol does not
reduce mortality or
recurrent stroke in
postmenopausal
women with
cerebrovascular
disease.
Continued on next page
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Table 2. Continued
Investigator/
Year Study Design Subjects Intervention
Median
Follow-Up End Point Results Conclusions
Hulley et al.
(5)/1998
(HERS)
Randomized, double-blind,
placebo-controlled
secondary prevention trial
2,763
postmenopausal
women with
CHD, mean age
66.7 yrs
CEE 0.625 
MPA 2.5 mg
(n  1,380)
or placebo
(n  1,383)
Mean 4.1 yrs CV events:
occurrence of
nonfatal MI or
CHD death
RR of 0.99 (0.80–1.22). Trend to
increased events in first year
with fewer events at years 4–5.
No overall CV benefit.
Possible divergence
at 4–5 yrs. HT
increased the rate of
thromboembolic
disease.
Grady et al.
(62)/2002
(HERS II)
As above As above As above Mean 6.8 yrs CV events: as above Unadjusted RR of 0.99
(0.81–1.22), adjusted 0.99
(0.84–1.17)
Lower rates of CHD
events at 4–5 yrs
among women on
HT in HERS did n
ot persist during
additional years of
follow-up.
Clarke et al.
(57)/2002
(PHASE)
Randomized, prospective
secondary prevention trial
255 postmenopausal
women with 1
coronary stenosis
50%, mean age
66.5 yrs
Transdermal EP
(n  134)
vs. placebo
(n  121)
30.8 mo CV events: MI,
cardiac death, or
admission to
hospital with
unstable angina
Event ratio 1.29 (0.84–1.95,
p  0.24)
HT group had a not
statistically
significantly higher
event rate compared
with control
subjects.
Roussouw et al.
(6)/2002
(WHI CEE
and MPA)
Randomized, double-blind,
placebo-controlled
primary prevention trial
16,608
postmenopausal
women
CEE 0.625 mg 
MPA 2.5 mg
(n  8,506) vs.
placebo
(n  8,102)
5.2 yrs
(planned
8.5 yrs)
CV events: primary
CHD outcome of
nonfatal MI, and
CHD death;
adverse risk score
included invasive
breast cancer
HR: CHD 1.29 (1.02–1.63),
breast cancer 1.26 (1.0–1.59),
stroke 1.41 (1.07–1.85), PE
2.13 (1.39–3.25), colon cancer
0.63 (0.43 –0.92), endometrial
cancer 0.83 (0.47–1.47), hip
fracture 0.66 (0.45–0.98), total
mortality 0.98 (0.82–1.18)
Stopped early for
absolute excess risks.
For 10,000 person-
years attributed to
HRT were 7 more
CHD events, 8
more PEs, 8 more
asive breast cancers;
whereas 6 fewer
colon cancers and 5
fewer hip fractures
were seen.
Anderson et al.
(63)/2004
(WHI-CEE
alone)
Randomized, double-blind,
placebo-controlled trial
primary prevention
10,379
postmenopausal
women with prior
hysterectomy
CEE 0.625 alone
(n  5,310)
vs. placebo
(n  5,429)
6.8 yrs CV events: as above HR for CHD events 0.91 (0.75–
1.12), breast cancer 0.77 (0.59–
1.01), stroke 1.39 (1.10–1.77),
PE 1.34 (0.87–2.06), colorectal
cancer 1.08 (0.75–1.55), hip
fracture 0.61 (0.41–0.91), total
mortality 1.04 (0.88–1.22)
The use of CEE
increases the risk of
stroke, decreases the
risk of hip fracture,
and does not affect
CHD incidence.
Abbreviations as in Table 1.
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oronary angiography showed no benefit (54 –56). In
omen who already had coronary disease (57) or increased
ubclinical atherosclerosis on carotid IMT assessment
58,59), HT had no impact on disease progression. Also in
study of postmenopausal women presenting with unstable
ngina, acute HT started in the hospital setting had no
ffect on reducing further ischemic events evaluated by
mbulatory electrocardiographic monitoring (60). Similarly,
T given to women with recent acute stroke did not reduce
ubsequent stroke or mortality (61).
The Heart and Estrogen/Progestin Replacement Study
HERS) was the first published secondary prevention trial
n 2,763 women with known CHD followed up for the
rimary outcome of the cardiovascular events of nonfatal
I or CHD death. At a mean of 4.1 years, there was no
ignificant difference in the HT arm versus the placebo arm
hazard ratio of 0.99, 95% confidence interval [CI] 0.80 to
.22) (5). There seemed to be a trend toward benefit at
onger durations of therapy, but this was not supported with
he longer follow-up period of seven years (hazard ratio of
.99, 95% CI 0.81 to 1.22) (62).
The largest randomized clinical trial is the Women’s
ealth Initiative (WHI), which included 16,608 women
ith an intact uterus randomized to CEE and medroxypro-
esterone acetate (MPA) or placebo with a 5.6-year mean
ollow-up (6). This was stopped early because of an increase
n breast cancer among HT users with no cardiovascular
enefit. An additional 10,739 women with hysterectomy
ere randomized to CEE alone or placebo, and that trial
lso showed no cardiovascular benefit (63). The findings for
he combined CEE-MPA arm suggested that for 10,000
erson-years there would be seven more CHD events, eight
ore strokes, eight more pulmonary embolisms, and eight
ore invasive breast cancers. For the CEE alone group,
here would be an absolute excess of 12 strokes per 10,000
eople despite a risk reduction of 6 fewer hip fractures. The
ISDOM trial (64), based in the United Kingdom with a
esign similar to the WHI trial, was discontinued in 2002
fter the results of the WHI trial were published.
Randomized placebo-controlled trials reduce many of the
iases inherent in observational studies but have other
imitations. The WHI trial is a very important study that
as changed the national view of HT. Although primarily a
rimary prevention trial, a small number of patients did have
stablished disease, including a history of MI (1.6%), history
f angina (2.8%), history of coronary bypass surgery/
ercutaneous coronary intervention (1.1%), history of stroke
0.7%), and/or CHD risk factors of diabetes (4.4%), hyper-
ension on therapy (35.7%), and hyperlipidemia on therapy
12.5%). The mean age of 63 years puts the majority of
hese women at least 10 years after menopause at the time
f initiation of HT. There was also significant crossover
etween the two arms. Of consideration, only one drug
egimen, CEE 0.625/MPA 2.5 mg orally per day, was
ested, so these findings may or may not apply to lower tosages of these drugs, other formulations, or other routes
f delivery.
UESTIONS TO BE ANSWERED
iven the findings of the HERS and of WHI trials, is the
T discussion ended for good? Hardly. The conflicting
esults from animal/observational studies compared with the
andomized controlled trials raise many unanswered ques-
ions. These include whether some of the discrepancy is
elated to the age of the women in the studies, the timing
f initiation (perimenopausal or postmenopausal), the
mount of atherosclerosis at the time of initiation (primary
s. secondary prevention), the dosage, and the preparation
orm (transdermal, oral, or intravenous with or without
rogesterone), and whether there are genetic aspects to
enefit or harm from HT.
Recently, Prentice et al. (65) reanalyzed the data from the
bservational trials adjusting for time from estrogen-plus-
rogestin initiation and confounding variables, and found
hat the readjusted hazard ratio estimates between the
bservational and experimental trials became much more
imilar for outcomes of CHD and thromboembolism,
lthough less so for stroke (65). These analyses suggest that
he apparent discrepancies between clinical trial and obser-
ational study findings may be substantially explained by
lassical confounding and differences in distributions of time
f initiation.
iming of initiation. Because atherosclerosis accelerates
fter estrogen deficiency, it would seem logical that estrogen
eplacement would have the most benefit when starting
arly in perimenopausal women. Most women in the ob-
ervational trials such as the Nurses’ Health Study, which
uggested a protective effect of estrogen, started HT during
he perimenopausal transition (66), whereas the WHI trial
ontained too few women in the perimenopausal period to
valuate whether any cardiac protection was seen. In the
HI trial the average age was 10 years after menopause, an
ge at which subclinical atherosclerosis has developed in
any women (67).
In support of the notion that timing of initiation is
ritical, animal studies also showed no benefit of estrogen in
nimals that already had artery damage, either from balloon
njury or from atherosclerotic diet, before initiation of HT
68). These animal studies are consistent with the findings
f the secondary prevention (i.e., HERS) trials. In post-
enopausal women in the Cardiovascular Health Study,
strogen replacement only caused vasodilation of the bra-
hial artery in younger women without clinical or subclinical
ardiovascular disease, suggesting that the favorable effects
f estrogen may be limited to only those in whom athero-
clerotic vascular disease has not yet developed (69).
The Kronos Early Estrogen Prevention Study (KEEPS)
s a multicenter randomized placebo-controlled clinical trial
hat will evaluate the effectiveness of 0.45 mg CEE or 50 g
ransdermal estradiol (in combination with 200 mg proges-
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May 2, 2006:1741–53 Hormone Therapy and the Cardiovascular Systemerone) in preventing the progression of carotid IMT or
oronary calcium in women who are within 36 months of
heir final menstrual period (70). It is hoped that the
EEPS trial will provide some answers to the important
uestion of whether HT will have a beneficial role if started
arly, although a relatively small sample size and the use of
surrogate end point represent limitations of this study.
odis et al. (71) have recently launched the Early vs. Late
ntervention Trial with Estrogen (ELITE), which is also
ocused on examining the potential importance of time since
enopause on the cardiovascular effects of HT. In the
LITE study, the effects of oral 17-estradiol on carotid
MT will be compared directly in perimenopausal women
ersus those 6 years after menopause.
ose. Although 0.625 mg CEE clearly showed no cardio-
ascular benefit in the HERS and WHI trials, the observa-
ional Nurses’ Health Study found the protective effect of
EE only in the lower doses of 0.3 mg and 0.625 mg,
hereas 1.25 mg and higher doses were not protective. In a
mall randomized, double-blind crossover trial by Koh et al.
13) of 57 postmenopausal women on progesterone, lower-
ose CEE 0.3 mg compared with 0.625 mg had similar
avorable effects on HDL, triglycerides, and brachial reac-
ivity, but had fewer prothrombotic effects and a smaller
ncrease in CRP. In postmenopausal diabetic women with-
ut a recent MI among the Kaiser Permanente database,
ow-dose or medium-dose estrogen (0.625 mg) decreased
he risk of MI, which was not seen with a higher dose (72).
hether a lower dose of estrogen such as 0.3 mg CEE
ould provide cardioprotection without increasing throm-
oembolism remains to be seen.
oute of delivery. The formulation of estrogen used in the
arge clinical trials and in the majority of the smaller studies
as CEE with or without MPA. There are extremely
imited randomized trial data for other preparations of HT.
ransdermal estrogen delivery provides sustained release of
strogens and more constant blood levels than oral admin-
stration. When estrogen is given orally, it has first-pass
ffects on the liver. Transdermal preparations avoid the
rst-pass effects on the liver and have less effect on the
ipoprotein profile (73). Estradiol-to-estrone conversion is
lower in parental administration, but transdermal delivery
ore commonly facilitates an estradiol-estrone ratio of
bout 1, which is similar to the physiological ratio in the
re-menopausal state.
Other differences that favor the transdermal approach
nclude a neutral effect on CRP, a decrease in factor VII and
brinogen, and a reduction in blood pressure (74). Because
he first pass through the liver is avoided, there may be less
nduction of a prothrombotic state with the transdermal
reparation. The Estrogen and Thromboembolism Risk
tudy Group (ESTHER) case-controlled trial found that
ral estrogen but not a transdermal formulation increased
he risk of venothromboembolism in postmenopausal
omen on HT compared with control subjects (75).In a case-controlled study, transdermal users seemed to
ave similar level of cardioprotective effects as those receiv-
ng oral preparations (46). These effects are not significant,
ut this may be attributable to small sample size. However,
n animal study using transdermal estradiol did not find
nhibition of aortic atherosclerosis (76).
Overall, the benefits of a transdermal estrogen prepara-
ion over an oral one seem encouraging, but further ran-
omized trials are warranted (77). It is hoped that the
EEPS trial (70), which will randomize healthy perimeno-
ausal women to oral versus transdermal hormone replace-
ent, will provide information on this important question.
enetics. It is possible that genetically determined sub-
roups of women may benefit by or be harmed from HT.
tudies have shown that the cardiovascular effects of HT
iffer in individuals with specific genetic variants of certain
enes such as apolipoprotein E4 () and myeloperoxidase
78,79). Recent work has also shown that genetic variation
n the estrogen receptor itself may modulate the cardiovas-
ular effects of HT, and also alter the underlying risk of
HD. The Herrington laboratory recently showed that a
pecific genetic variant of ER is associated with an
nhanced HDL-increasing effect of HT (80). Quite surpris-
ngly, this same genetic variant of ER was also recently
hown to be associated with an approximately three-fold
ncreased risk of MI in men in the Framingham heart
tudy (81).
tatin use. Perhaps concomitant statin use may attenuate
he negative cardiovascular effects of HT. Subgroup analysis
f the HERS trial showed that the increased cardiovascular
isks of HT in this population of women with established
HD did not occur in women taking statin therapy;
owever, there was no incremental risk reduction for car-
iovascular events in women on both statin and HT
ompared with statin alone (82).
ummary. In conclusion, the HT controversy has not yet
een laid to rest. Current randomized clinical trial data
upport the American Heart Association/American Col-
ege of Cardiology guidelines that HT should not be
rescribed for prevention of cardiovascular disease
83,84). However, it remains possible that some formu-
ations and doses of HT may have favorable cardiovas-
ular benefits when initiated earlier in the pre-
enopausal or perimenopausal period in women without
re-existing atherosclerotic disease. We await the
EEPS and ELITE trial results, among others, to
urther answer this important issue.
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